NCT07500727 Skeletal Muscle Aging and Responsiveness in Aged People With MS
| NCT ID | NCT07500727 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oklahoma Medical Research Foundation |
| Condition | Multiple Sclerosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2026-03-06 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2026-03-06 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purposes of this study are to: 1) compare baseline muscle and cardiovascular health in older individuals (\>60 years old) diagnosed with MS to age-matched people without MS, 2) determine muscle and whole body changes to an exercise training program, 3) determine if the muscle in a more affected leg in individuals diagnosed with MS is different from the muscle of a less affected leg, and 4) if or how individuals diagnosed with MS adapt differently than age-matched people without MS to exercise training. Participation in this study will average 1.5 hours per visit, 3 visits per week, for approximately 4 months.
Eligibility Criteria
Inclusion Criteria: * 1\. Male or female aged 60 or above 2. Free of unmanaged chronic diseases other than multiple sclerosis 3. No structured exercise program (2 or more bouts/wk) within previous 6 months 4. Cognitively capable of providing informed consent 5. Must meet EDSS score between 2 to 5.5 during screening Exclusion Criteria: * 1\. Neuromuscular or musculoskeletal disorder, other than multiple sclerosis, that would limit the ability to perform the exercise and/or testing bouts. 2\. Cardiopulmonary disorders or reduced breathing capacity 3\. Metabolic diseases including markers of liver disease (ALT \> 52 U/dl) and type 2 diabetes (HbA1C ≥ 6.5, fasting blood glucose ≥ 126 mg/dl) 4\. Taking any dose of metformin 5\. Any other disease or disorder that would influence exercise response (e.g., chronic kidney disease, Alzheimer's, current cancer diagnosis or within 2 yr remission, cerebrovascular) 6\. History of Chemotherapy within 5 years 7\. Unchangeable anticoagulant (Coumadin, Pradaxa, etc.) use. To be determined by clinical staff. 8\. Insulin sensitizing/blood glucose lowering (e.g., metformin) or metabolic (GLP1 agonists) drugs. 9\. High dose statin (40 mg and above) 10\. Have a non-correctable visual impairment 11\. Score less than 29 on the Symbol Digit Test 12\. Received Botox for spasticity within the prior 3 months of study participation. 13\. Cannot have any adjustments to Baclofen during study participation. 13\. Unable to commit to \~4 months required to complete the study. 14\. Lidocaine allergy 15\. Tobacco use 16\. Excessive alcohol consumption (3 drinks/d or 7 drinks/wk for females; 4 drinks/day or drinks/wk for males) 17\. BMI greater than 35.0 kg/m2
Contact & Investigator
Benjamin F Miller, Ph.D.
PRINCIPAL INVESTIGATOR
Oklahoma Medical Research Foundation
Frequently Asked Questions
Who can join the NCT07500727 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07500727 currently recruiting?
Yes, NCT07500727 is actively recruiting participants. Contact the research team at lena-fuentes@omrf.org for enrollment information.
Where is the NCT07500727 trial being conducted?
This trial is being conducted at Oklahoma City, United States.
Who is sponsoring the NCT07500727 clinical trial?
NCT07500727 is sponsored by Oklahoma Medical Research Foundation. The principal investigator is Benjamin F Miller, Ph.D. at Oklahoma Medical Research Foundation. The trial plans to enroll 10 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.